癌症治疗期间细菌操纵子的扩增改善氟嘧啶类毒性
本研究通过对结直肠癌(CRC)治疗期间人体肠道微生物组进行纵向分析,并结合细胞培养与小鼠实验,发现口服氟嘧啶治疗期间肠道微生物群落结构及嘧啶相关基因丰度发生显著变化。preTA操纵子丰度足以使活性代谢产物5-氟尿嘧啶(5-FU)失活,且preTA丰度与患者氟嘧啶毒性呈负相关,提示人肠道细菌操纵子与癌症治疗剂量限制性副作用之间存在因果且具临床相关性的相互作用。
要点
- 口服氟嘧啶治疗期间,肠道微生物群落结构及嘧啶相关基因丰度出现显著变化,preTA操纵子富集。
- preTA+细菌可在离体肠道微生物群及小鼠远端肠道中清除5-FU。
- preTA丰度与患者氟嘧啶毒性呈负相关,支持其因果及临床相关性。
核心结论
- 人肠道细菌操纵子preTA的丰度与氟嘧啶类抗癌治疗的剂量限制性毒性存在因果且具临床相关性的相互作用,preTA丰度与患者氟嘧啶毒性呈负相关。
研究设计与样本
- 研究纳入接受口服氟嘧啶治疗的结直肠癌(CRC)患者队列(NCT04054908),对患者肠道微生物组进行纵向分析,并结合细胞培养、离体患者来源群落及小鼠实验。
- 采用16S rRNA基因测序分析多个患者队列、小鼠小肠和大肠内容物以及患者来源离体群落的微生物群落结构。
- 采用宏基因组测序分析口服氟嘧啶治疗期间嘧啶相关基因丰度变化;使用无菌小鼠和抗生素处理小鼠进行定植实验,定植物包括小鼠肠道微生物群、preTA+大肠杆菌(Escherichia coli)或preTA高的CRC患者粪便。
主要发现
- 16S rRNA基因测序显示,口服氟嘧啶治疗期间多个患者队列、小鼠小肠和大肠内容物以及患者来源离体群落的肠道微生物群落结构出现显著变化。
- 宏基因组测序显示,口服氟嘧啶治疗期间嘧啶相关基因丰度出现明显变化,包括preTA操纵子富集,该操纵子足以使活性代谢产物5-氟尿嘧啶(5-FU)失活。
- preTA+细菌在离体培养的肠道微生物群和小鼠远端肠道中清除5-FU。
- 无菌小鼠和抗生素处理小鼠的氟嘧啶毒性增加,定植小鼠肠道微生物群、preTA+大肠杆菌(Escherichia coli)或preTA高的CRC患者粪便后可逆转该毒性增加。
- preTA丰度与患者氟嘧啶毒性呈负相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Dose-limiting toxicities remain a major barrier to drug development and therapy, revealing the limited predictive power of human genetics. Here, we demonstrate the utility of a more comprehensive approach to studying drug toxicity through longitudinal profiling of the human gut microbiome during colorectal cancer (CRC) treatment (NCT04054908) coupled to cell culture and mouse experiments. Substantial shifts in gut microbial community structure during oral fluoropyrimidine treatment across multiple patient cohorts, in mouse small and large intestinal contents, and in patient-derived ex vivo communities were revealed by 16S rRNA gene sequencing. Metagenomic sequencing revealed marked shifts in pyrimidine-related gene abundance during oral fluoropyrimidine treatment, including enrichment of the preTA operon, which was sufficient for the inactivation of active metabolite 5-fluorouracil (5-FU). preTA+ bacteria depleted 5-FU in gut microbiota grown ex vivo and in the mouse distal gut. Germ-free and antibiotic-treated mice experienced increased fluoropyrimidine toxicity, which was rescued by colonization with the mouse gut microbiota, preTA+ Escherichia coli, or preTA-high stool from patients with CRC. Last, preTA abundance was negatively associated with fluoropyrimidine toxicity in patients. Together, these data support a causal, clinically relevant interaction between a human gut bacterial operon and the dose-limiting side effects of cancer treatment. Our approach may be generalizable to other drugs, including cancer immunotherapies, and provides valuable insights into host-microbiome interactions in the context of disease.
引用
- Trepka KR, Kidder WA, Kyaw TS, et al. Expansion of a bacterial operon during cancer treatment ameliorates fluoropyrimidine toxicity. Sci Transl Med. 2025. PMID: 40238917. doi:10.1126/scitranslmed.adq8870
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。